Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • These results suggest that sunitinib is a cost-effective alternative to IFN-alpha as a first-line treatment for mRCC.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.13.2662

PubMed ID

  • 18711190

Additional Document Info

start page

  • 3995

end page

  • 4000

volume

  • 26

number

  • 24